UCL Chemical Engineering has successfully participated in a GBP 10M+ bid led by the UCL School of Pharmacy, University of Nottingham and the Synthesis & Solid State Pharmaceutical Centre in Ireland, to fund a new EPSRC Centre for Doctoral Training in Transformative Pharmaceutical Technologies.
This major award of £6.1m from the Engineering and Physical Sciences Council in the UK and €3.0m from Science Foundation Ireland (plus significant contribution from industry) will allow us to train to doctoral level 75 inspired and strategic-thinking scientists ready for high achieving careers in the UK and Ireland pharmaceutical and healthcare sectors. Co-funded by 19 industrial partners ranging from small biotechs to global pharmaceutical businesses, the Centre will create new science and educate a new cadre of scientists to transform challenging active ingredients from drug discovery and biotechnology technologies into potent medicines.
UCL Chemical Engineering Associate Professor, Stefan Guldin is one of ten Investigators who worked closely on the CDT proposal bid. He had this to say:
This award builds on a very successful doctoral training programme led by the UCL School of Pharmacy and will promote a cross-disciplinary approach to develop future leaders and provide innovative solutions to the pharmaceutical industry. We are delighted to play an active role in this initiative to provide an engineering perspective.
Currently 15 fully funded studentships are offered, commencing in September 2019.
Further information
EPSRC CDT in Transformative Pharmaceutical Technologies homepage
http://www.transpharmtech-dtc.ac.uk
This release was first published 8 February 2019 by University College London.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
